Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| MENTOR GRAPH | MENT | 2.62% |
| GENTIUM SPA | GENT | 2.47% |
| INFORMATION | III | 2.09% |
| AMER NATL BK | AMNB | 1.99% |
| BARRETT BUSI | BBSI | 1.93% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
MWV Specialty Chemicals, a division of MeadWestvaco Corporation (MWV - Analyst Report), has agreed to buy the remaining shares of Resitec Industria Quimica, Ltda, a leader in the development of chemical product solutions in Brazil. For the last four years, MeadWestvaco owned Resitec in a 50-50 joint venture with South Africa-based AECI Limited. The financial terms of the transaction were not disclosed.
Resitec is a leading producer of emulsifiers for synthetic rubbers and other elastomers. It owns a manufacturing facility located in the city of Duque de Caxias, Rio de Janeiro. It also has an oil refinery in the city of Palmeira, Santa Catarina, Brazil.
Resitec produces chemical products for the rubber, lubricants, food and adhesive markets. Post acquisition, it will also serve in the asphalt and oilfield markets. It exports its products to elastomers, lube-oils and adhesives, among many other markets in the U.S., Latin America, Southeast Asia and Europe.
MeadWestvaco decided to buy Resitec to fortify its core pine chemical business in Brazil and Latin America. It intends to augment its product portfolio to reach a wider client base. Further, it will give MeadWestvaco the opportunity to serve and grow in the profitable and expanded markets of oilfield, adhesives and paving solutions.
The acquisition fits well with MeadWestvaco’s strategy that includes significant investments in Brazil which is recovering moderately. The market demand is also returning to normal in the region.
MeadWestvaco has operated in Brazil for nearly 60 years. MWV Rigesa is a leader in the Brazilian corrugated packaging market. The company started up the new paperboard machine in Brazil during third-quarter 2012, which is expected to add to its earnings and cash flows in 2013.
However, the inflationary pressure, particularly on wages, will be headwind for MeadWestvaco. Therefore, the company has to focus on improving its pricing and product mix.
MeadWestvaco’s third-quarter 2012 adjusted earnings of 39 cents per share were in line with the Zacks Consensus Estimate. Total revenues remained flat year over year at $1.40 billion in the reported quarter, surpassing the Zacks Consensus Estimate of $1.37 billion.
MeadWestvaco retains a short-term Zacks #3 Rank (Hold). We have a long-term Neutral recommendation on the stock.
Read the full Analyst Report on MWV